Page 90 - GUIAS ESC ESH 2018

90 ESC/ESH Guidelines

.
MJ, British Hypertension Society’s PATHWAY Studies Group. Spironolactone . . 329. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe
versus placebo, bisoprolol, and doxazosin to determine the optimal treatment . . K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi
for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, . . . Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular
crossover trial. Lancet 2015;386:2059–2068. . . Events Trial Group. Prevention of cardiovascular events with calcium channel
311. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, . . blocker-based combination therapies in patients with hypertension: a random-
treatment intensification, and control in Western Europe and the United . . . ized controlled trial. J Hypertens 2011;29:1649–1659.
States. Arch Intern Med 2007;167:141–147. . . 330. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder
312. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. . . P, Zanchetti A, Group SS. The Study on Cognition and Prognosis in the Elderly
Better compliance to antihypertensive medications reduces cardiovascular risk. . . (SCOPE): principal results of a randomized double-blind intervention trial. J
J Hypertens 2011;29:610–618. . . . Hypertens 2003;21:875–886.
313. Tiffe T, Wagner M, Rucker V, Morbach C, Gelbrich G, Stork S, Heuschmann . . 331. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, Group FS. The Felodipine
PU. Control of cardiovascular risk factors and its determinants in the general . . Event Reduction (FEVER) Study: a randomized long-term placebo-controlled
population- findings from the STAAB cohort study. BMC Cardiovasc Disord . . . trial in Chinese hypertensive patients. J Hypertens 2005;23:2157–2172.
2017;17:276. . . 332. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt
314. Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. . . CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C,
Cardiol Clin 2010;28:609–622. . . O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised
315. Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Gulsin GS, Beech A, Maresova . . . double-blind comparison of placebo and active treatment for older patients
V, Topham PS, Stanley A, Thurston H, Smith PR, Horne R, Widimsky J, Keavney . . with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-
B, Heagerty A, Samani NJ, Williams B, Tomaszewski M. Biochemical screening . . Eur) Trial Investigators. Lancet 1997;350:757–764.
for nonadherence is associated with blood pressure reduction and improve- . . 333. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hyper-
ment in adherence. Hypertension 2017;70:1042–1048. . . . tension in the elderly. Systolic Hypertension in China (Syst-China)
316. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research . . Collaborative Group. Arch Intern Med 2000;160:211–220.
Group. Major outcomes in high-risk hypertensive patients randomized to . . 334. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO,
angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: . . Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack . . . in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in
Trial (ALLHAT). JAMA 2002;288:2981–2997. . . Old Patients with Hypertension-2 study. Lancet 1999;354:1751–1756.
317. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist . . 335. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A,
F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, . . . Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO,
Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and . . Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with
mortality in the Losartan Intervention For Endpoint reduction in hypertension . . conventional therapy on cardiovascular morbidity and mortality in hyperten-
study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003. . . sion: the Captopril Prevention Project (CAPPP) randomised trial. Lancet
318. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, . . . 1999;353:611–616.
Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, . . 336. Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, Mancia G.
Ostergren, J, ASCOT Investigators. Prevention of cardiovascular events with an . . Prevalence and incidence of the metabolic syndrome in the European
antihypertensive regimen of amlodipine adding perindopril as required versus . . . Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-
atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian . . media thickness. J Hypertens 2007;25:2463–2470.
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a mul- . . 337. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T,
ticentre randomised controlled trial. Lancet 2005;366:895–906. . . Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A,
319. McKavanagh P, Lusk L, Ball PA, Verghis RM, Agus AM, Trinick TR, Duly E, Walls . . . VALUE trial group. Outcomes in hypertensive patients at high cardiovascular
GM, Stevenson M, James B, Hamilton A, Harbinson MT, Donnelly PM. A com- . . risk treated with regimens based on valsartan or amlodipine: the VALUE rando-
parison of cardiac computerized tomography and exercise stress electrocardio- . . mised trial. Lancet 2004;363:2022–2031.
gram test for the investigation of stable chest pain: the clinical results of the . . . 338. PROGRESS Collaborative Group. Randomised trial of a perindopril-based
CAPP randomized prospective trial. Eur Heart J Cardiovasc Imaging . . blood-pressure-lowering regimen among 6,105 individuals with previous stroke
2015;16:441–448. . . or transient ischaemic attack. Lancet 2001;358:1033–1041.
320. Hedner T. Progress report on the Nordic diltiazem study (NORDIL): an out- . . 339. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen
come study in hypertensive patients. Blood Press 1999;8:296–299. . . . JO, Lanke J, de Faire U, Dahlof B, Karlberg BE. Randomised trial of effects of cal-
321. Elgendy IY, Bavry AA, Gong Y, Handberg EM, Cooper-DeHoff RM, Pepine CJ. . . cium antagonists compared with diuretics and beta-blockers on cardiovascular
Long-term mortality in hypertensive patients with coronary artery disease: . . morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL)
results from the US cohort of the International Verapamil (SR)/Trandolapril . . study. Lancet 2000;356:359–365.
Study. Hypertension 2016;68:1110–1114. . . . 340. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli
322. Coope J, Warrender TS. Randomised trial of treatment of hypertension in eld- . . FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA,
erly patients in primary care. Br Med J (Clin Res Ed) 1986;293:1145–1151. . . Kolb HR, Bakris GL, Cohen JD, Parmley WW, Investigators I. A calcium antago-
323. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive . . nist vs a non-calcium antagonist hypertension treatment strategy for patients
drug treatment in older persons with isolated systolic hypertension. Final . . . with coronary artery disease. The International Verapamil-Trandolapril Study
results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA . . (INVEST): a randomized controlled trial. JAMA 2003;290:2805–2816.
1991;265:3255–3264. . . 341. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus
324. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. . . . monotherapy in reducing blood pressure: meta-analysis on 11,000 participants
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension . . from 42 trials. Am J Med 2009;122:290–300.
(STOP-Hypertension). Lancet 1991;338:1281–1285. . . 342. MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK,
325. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive . . Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes
drugs. J Hypertens 2006;24:3–10. . . . G, Brown MJ, British Hypertension Society Programme of Prevention And
326. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, . . Treatment of Hypertension With Algorithm-based Therapy (PATHWAY).
Ruilope LM. Morbidity and mortality in patients randomised to double-blind . . Combination therapy is superior to sequential monotherapy for the initial treat-
treatment with a long-acting calcium-channel blocker or diuretic in the . . . ment of hypertension: a double-blind randomized controlled trial. J Am Heart
International Nifedipine GITS study: Intervention as a Goal in Hypertension . . Assoc 2017;6:e006986.
Treatment (INSIGHT). Lancet 2000;356:366–372. . . 343. Yusuf S, Lonn E, Pais P, Bosch J, Lopez-Jaramillo P, Zhu J, Xavier D, Avezum A,
327. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, . . Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I,
Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators. Benazepril plus amlo- . . . Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM,
dipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J . . Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A,
Med 2008;359:2417–2428. . . Dagenais G, HOPE-3 Investigators. Blood-pressure and cholesterol
328. Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Teramukai S, . . lowering in persons without cardiovascular disease. N Engl J Med 2016;374:
Higaki J, Ito S, Shimada K, COLM Investigators. Combination therapy of hyper- . . . 2032–2043.
tension in the elderly: a subgroup analysis of the Combination of OLMesartan . . 344. Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pressure tar-
and a calcium channel blocker or diuretic in Japanese elderly hypertensive . . get, time to intensification, and time to follow-up in treatment of hypertension:
patients trial. Hypertens Res 2015;38:89–96. . . . . population based retrospective cohort study. BMJ 2015;350:h158.

Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy339/5079119
by guest
on 27 August 2018